<DOC>
	<DOCNO>NCT01305694</DOCNO>
	<brief_summary>The study phase I/II trial design establish safety efficacy intravenous administration bone marrow derive mesenchymal stem cell related donor patient relapsed/refractory aplastic anemia .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Transplantation Patients With Relapsed/Refractory Aplastic Anemia .</brief_title>
	<detailed_description>Aplastic anemia ( AA ) autoimmune hematologic stem cell disease mediate activated T-lymphocytes lead bone marrow dysfunction . In presence empty marrow , pancytopenia , transfusion dependence , severity disease base neutrophil ( PMN ) count : nonsevere AA ( nSAA ; PMN &gt; 0.5 × 109/L ) , severe AA ( SAA ; PMN 0.2- 0.5 × 109/L ) , severe AA ( vSAA ; PMN &lt; 0.2 × 109/L ) . Patients nSAA offer supportive care , anabolic steroid , and/or low-dose steroid cyclosporine ( CsA ) .Patients SAA vSAA offer immunosuppressive treatment involve injection Anti-thymocyte globulin ( ATG ) combination cyclosporine ( CsA ) . However , nSAA patient remain dependent transfusion , treatment response ATG SAA best 50-60 % ,30 % -40 % patient relapse follow initial response treatment , also HLA-matched donor bone marrow transplantation . These patient high risk die without additional treatment . Since prognosis refractory relapse AA patient remain poor , need safe effective therapy improve response rate remission duration refractory relapse AA . Mesenchymal stem cell ( MSCs ) part bone marrow stem cell repertoire . The main role MSCs support hematopoiesis . Recently , significant interaction MSCs cell immune system demonstrate : MSCs find downregulate T B lymphocytes , natural killer cell ( NK ) antigen present cell various mechanism , include cell-to-cell interaction soluble factor production . MSCs fully suppress T cell function involve degree MSC activation 'licensing ' think involve interferon ( IFN ) -γ conjunction IL-1α , IL-1β tumour necrosis factor-a . Non-specific suppression T cell proliferation mediate soluble factor transform growth factor ( TGF ) -β , kynurenine , prostaglandin E2 ( PGE2 ) , nitric oxide , haem oxygenase product insulin-like growth factor bind protein . Since haematopoietic support immunomodulatory effect , bone marrow-derived human MSCs transplantation maybe safe novel therapeutic approach patient refractory relapse AA .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>Patients must fulfill definition aplastic anaemia : There must least two follow : haemoglobin &lt; 100g/L ; platelet count &lt; 50 x 109/L ; neutrophil count &lt; 1.5 x 109/L , hypocellular bone marrow ; SAA define hypocellular bone marrow &lt; 25 % cellularity two following : neutrophil count &lt; 0.5 x 109/L platelet &lt; 20 x 109/L reticulocyte &lt; 20 x 109/L nSAA define hypocellular bone marrow cytopenia least two cell line neutrophil count &gt; 0.5 x 109/L , red cell and/or platelet transfusion dependence . Patients belong acquire aplastic anaemia . Patients history SAA must incomplete response least 3 month follow treatment ATG/CsA , must relapse follow initial response treatment , HLAmatched donor bone marrow transplantation . Patients history nSAA must red cell and/or platelet transfusion dependence . Peripheral blood count time enrollment must include least one following : haemoglobin &lt; 90 g/L red blood cell ( RBC ) transfusion dependence , PMN &lt; 1 x 109/L , platelet count &lt; 50 x 109/L . Patients must organ function define : total bilirubin within normal institutional limit ( NV : 0.020.5 umol/L ) AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 × institutional upper limit normal AST ( NV : 035 U/L ) ; ALT ( NV : 040 U/L ) Creatinine within normal institutional limit ( NV : 53106 umol/L ) Creatinine clearance &gt; 1.25 ml/s patient creatinine level institutional normal . Age minimum 16 year old upper age limit . Ability understand willingness sign write informed consent document . Patients may receive investigational agent within 4 week study entry . History allergic reaction attribute compound similar biologic composition mesenchymal stem cell . Current diagnosis Fanconi 's anemia , Dyskeratosis Congenita ( DC ) hereditary form AA . Psychiatric , addictive disorder compromise ability give truly informed consent . Age &lt; 16 year old . ECOG performance status &gt; 2 . Malignancy within last 5 year . Uncontrolled intercurrent illness include , limited , ongoing active infection ( defined invasive fungal infection progressive CMV viremia ) , symptomatic congestive heart failure ( NYH class III IV ) , unstable angina pectoris , cardiac arrhythmia . Pregnant breastfeed woman . HIVpositive patient .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>